Kyverna Therapeutics (KYTX) announced the appointment of Greg Martini as CFO, effective May 18. Martini succeeds Marc Grasso who will be consulting for the company to ensure a transition. With this appointment, Martini will lead Kyverna’s financial strategy and operations, including corporate finance, capital allocation, and investor relations. Martini joins Kyverna from Ironwood (IRWD) where he most recently served as senior VP and CFO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
- Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
- Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
- Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
- Kyverna Therapeutics Appoints Chief Commercial Officer for Growth